TheStreet.com  Jan 15  Comment 
NEW YORK (TheStreet) -- Goldman Sachs upgraded Eli Lilly and Co. stock today to "neutral" from "sell" and raised its price target to $70 from $65. "We believe LLY has turned the corner with improving margins and new product launches driving...
Market Intelligence Center  Jan 15  Comment 
Eli Lilly and Co (LLY) was selected by MarketIntelligenceCenter.com’s trade-picking algorithms today after trading between $68.71 and $69.88 on Wednesday before closing at $69.76. A diagonal spread using a long position in the Jan. '16 $52.50...
Benzinga  Jan 14  Comment 
Citigroups' Jonathan Eckard, Ph.D. continues to believe that Alkermes Plc (NASDAQ: ALKS) is a top name among biotech stocks and remains on the Citi U.S. Focus List. On Wednesday, Eckard increased his price target on Buy-rated Alkermes to $85...
TheStreet.com  Jan 13  Comment 
NEW YORK (TheStreet) -- Shares of Bristol-Myers Squibb  rose 1.54% to $63.14 in late morning trading Tuesday after the pharmaceutical company began a clinical collaboration with Eli Lilly  . Bristol-Myers and Eli Lilly will collaborate...
FierceBiotech  Jan 13  Comment 
Eli Lilly is buying big into the idea that the latest and greatest cancer therapies can work even better in combination, inking agreements to study its drugs alongside immunotherapies from Merck and Bristol-Myers Squibb.
Jutia Group  Jan 13  Comment 
[Reuters] - Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new ... Read more on this. Eli...
Wall Street Journal  Jan 13  Comment 
Eli Lilly reached separate agreements to collaborate on clinical trials of immunotherapy drugs from Merck and Bristol-Myers Squibb.
Benzinga  Jan 12  Comment 
Eli Lilly and Co (NYSE: LLY) has witnessed a continuous rally since last year, up 33 percent in that time frame. Eli Lilly CEO John Lechleiter was on CNBC Monday to discuss the outlook for the healthcare sector and the new drugs that he is most...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki